TCT和DNA倍体分析在子宫良性疾病术前检查中的临床价值

The clinical value of associated pre-operation screening by TCT and DNA ploidy analysis for patients with benign uterine diseases

目的:探讨液基细胞学检查(TCT)技术和DNA倍体分析系统在子宫良性肿瘤术前检查中的临床价值及其重要性。方法:回顾性总结子宫良性病变158例患者,术前行宫颈脱落细胞TCT和DNA倍体分析,以术后病理诊断为标准,计算两种方法对宫颈病变的检出阳性率。结果:DNA倍体分析中见异倍体的50例,阳性检出率为76.0%(38/50);TCT检测阳性者98例,CIN和宫颈癌49例,阳性检出率为50%(49/98)。结论:对于子宫良性病变需行全子宫切除术的患者,应以TCT检查和DNA倍体分析相结合的方法常规筛查,以提高宫颈病变检出率,确定手术方案。

Objective To assess the clinical value and importance of associated screening by TCT and DNA ploidy anal-ysis in cervical epithelia for pre-operation patients with benign uterine diseases. Methods Retrospective analysis of the data of TCT and DNA ploidy in 158 patients pre-operated with benign uterine diseases ,and two positive rates were carried out according to the pathological standard after operation. Results Positive rate is 76.0% in 50 patients with DNA ploidy and it is 50% in 98 patients detected by ...